Mr. Gregory Dellino, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 9008 W Caelen Ave, Cheney, WA 99004 Phone: 425-737-3762 |
Mrs. Julie A. Carstens, MOTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 12414 S Andrus Rd, Cheney, WA 99004 Phone: 509-559-4507 |
Krystal Marie Seitz, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 2219 N 6th St, Cheney, WA 99004 Phone: 509-235-6196 |
News Archive
Scripps Research Institute scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances. The new findings could have a profound effect on the development of new therapies for a number of disorders, including schizophrenia and depression.
Researchers who study the physics of fluids are learning why certain situations increase the risk that droplets will transmit diseases like COVID-19.
A major collaboration between US research centers has highlighted three factors that could ultimately determine whether an outbreak of influenza becomes a serious epidemic that threatens national health. The research suggests that the numbers in current response plans could be out by a factor of two or more depending on the characteristics of the particular pandemic influenza.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases.
Understanding that not all bladder cancers are the same, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have created a tool that may help them to uncover why only a fraction of patients respond to new immune-based treatments.
› Verified 4 days ago